Patent-Protected Licensing Product Pipeline: Oncology


  • HER3-targeted Eosomes with doxorubicin payload in preclinical development
  • Applications: Triple-negative breast cancer and hard-to-treat HER2+ refractory or drug resistant cancers. Both express highly elevated levels of HER3 receptor. Extensive scientific data is available validating the advantages and utility of Eos-001 in cancer cell lines, (breast, ovarian, prostate and glioblastoma) and xenograft mouse models for human cancer
  • Observations
    • Lower dose of targeted doxorubicin required
    • Improved safety profile for targeted doxorubicin (e.g. no damage to heart tissue)
    • Eos-001 is highly effective against first-line drug-resistant breast cancer cells and tumors
    • Three (3) issued patents and a number of patent applications

Eos-001 Competition: Other Doxorubicin Products
Currently, doxorubicin is marketed either in native form (generic product), as liposomal formulation (branded product), or conjugated to albumin.  In addition, other forms of nanoparticle-based doxorubicin approaches are being investigated. In addition to the unique structural properties of our Eosomes technology, Eos-001 differentiates from other marketed products in very impactful ways:

    • Eos-001 is a specifically targeted product that delivers doxorubicin to the interior of the target cell limiting systemic exposure and resulting in higher efficacy at a lower dose and improved safety profile
    • Eos-001 is uniquely highly active against HER2+ cells and tumors resistant to first-line therapies, and triple-negative breast cancer tumors


  • C-Met targeted Eosomes with doxorubicin payload
  • Applications: Drug-resistant and metastatic solid tumors that express elevated levels of c-Met
  • US and International Patent applications